NCT03367533 is a Phase 1 clinical trial of Ketamine in Depressive Disorder, Major, sponsored by Yale University.

Who is sponsoring NCT03367533?

NCT03367533 is sponsored by Yale University.

What drugs are being tested in NCT03367533?

Interventions in NCT03367533: Ketamine, Perampanel, Placebo.

What condition does NCT03367533 study?

NCT03367533 studies Depressive Disorder, Major, Post Traumatic Stress Disorder, Bipolar Disorder.

Is NCT03367533 still recruiting?

NCT03367533 is currently completed. Last updated 7 February 2025.

Last reviewed 2025-02-07 · How we verify

NCT03367533

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial

Completed Phase 1 Last updated 7 February 2025

What this trial tests

Phase 1 trial testing Ketamine in Depressive Disorder, Major in 13 participants. Completed in 8 July 2022.

Timeline

29 November 2018

Primary endpoint
8 July 2022

8 July 2022

Quick facts

Lead sponsor	Yale University
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	13
Start date	29 November 2018
Primary completion	8 July 2022
Estimated completion	8 July 2022
Sites	1 location across United States

Drugs / interventions tested

Ketamine (ketamine) — full drug profile →
Perampanel (PERAMPANEL) — full drug profile →
Placebo

Conditions studied

Depressive Disorder, Major — all drugs for Depressive Disorder, Major →
Post Traumatic Stress Disorder — all drugs for Post Traumatic Stress Disorder →
Bipolar Disorder — all drugs for Bipolar Disorder →

Sponsor

Yale University

Who can join

Adults 18 to 65, any sex, with Depressive Disorder, Major or Post Traumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
Hashimoto K. · · 2019 · cited 222× · PMID 31215725 · DOI 10.1111/pcn.12902
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.
Wei Y, Chang L, Hashimoto K. · · 2022 · cited 164× · PMID 33963284 · DOI 10.1038/s41380-021-01121-1
Pharmacological Discrimination of Effects of MK801 on Thalamocortical, Mesothalamic, and Mesocortical Transmissions.
Okada M, Fukuyama K, Nakano T, Ueda Y. · · 2019 · cited 28× · PMID 31752219 · DOI 10.3390/biom9110746
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression.
Vecera CM, C Courtes A, Jones G, Soares JC, et al · · 2023 · cited 23× · PMID 38004437 · DOI 10.3390/ph16111572

Verify or expand the search:

Other trials of Ketamine

Trials testing the same drug.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT06963294 — Ketamine and Dexmedetomidine for Delirium in Joint Arthroplasty · NA · not yet recruiting
NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
NCT07197684 — Ultrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surg · NA · not yet recruiting
NCT06231563 — Ketamine for Veterans With Parkinson's Disease · Phase 2 · recruiting

Other recruiting trials for Depressive Disorder, Major

Currently open trials in the same condition.

NCT07227454 — A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder · Phase 3 · recruiting
NCT07258485 — A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major · recruiting
NCT07059234 — The Motor Activity - Subjective Energy (MASE) Project · NA · recruiting
NCT06982820 — Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia · NA · recruiting
NCT05553353 — Dosing rTMS for Depression Post-SCI · NA · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03367533 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 7 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03367533.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing